Alkermes (NASDAQ:ALKS) Price Target Raised to $50.00 at Needham & Company LLC

Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Needham & Company LLC from $45.00 to $50.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 37.93% from the company’s previous close.

ALKS has been the subject of several other reports. Wall Street Zen cut shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Wolfe Research began coverage on shares of Alkermes in a research report on Monday, February 23rd. They issued an “outperform” rating and a $45.00 price objective for the company. Royal Bank Of Canada decreased their price objective on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Weiss Ratings raised shares of Alkermes from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, April 27th. Finally, Truist Financial upgraded shares of Alkermes to a “strong-buy” rating in a research note on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Alkermes presently has a consensus rating of “Moderate Buy” and an average target price of $44.71.

Alkermes Stock Performance

ALKS stock opened at $36.25 on Wednesday. The stock has a market capitalization of $6.03 billion, a P/E ratio of 25.35 and a beta of 0.31. Alkermes has a one year low of $25.17 and a one year high of $36.56. The company has a 50 day moving average price of $31.53 and a two-hundred day moving average price of $30.98.

Alkermes (NASDAQ:ALKS) last released its earnings results on Saturday, February 14th. The company reported $0.29 EPS for the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The firm had revenue of $384.55 million during the quarter. Research analysts forecast that Alkermes will post -0.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $30.00, for a total value of $180,000.00. Following the sale, the senior vice president owned 109,769 shares in the company, valued at approximately $3,293,070. This trade represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David Joseph Gaffin sold 2,034 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.20, for a total transaction of $67,528.80. Following the transaction, the executive vice president owned 231,558 shares in the company, valued at $7,687,725.60. This represents a 0.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 39,102 shares of company stock worth $1,265,090. 4.59% of the stock is owned by company insiders.

Institutional Trading of Alkermes

Large investors have recently added to or reduced their stakes in the business. Assetmark Inc. boosted its holdings in Alkermes by 933.8% during the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after buying an additional 747 shares in the last quarter. Cullen Frost Bankers Inc. acquired a new position in Alkermes in the 4th quarter worth approximately $28,000. Johnson Financial Group Inc. acquired a new stake in shares of Alkermes during the 3rd quarter valued at $31,000. UMB Bank n.a. boosted its stake in shares of Alkermes by 57.6% during the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after buying an additional 446 shares during the period. Finally, Salomon & Ludwin LLC boosted its stake in shares of Alkermes by 115.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after buying an additional 667 shares during the period. 95.21% of the stock is currently owned by institutional investors.

Key Headlines Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Q1 results beat expectations — Alkermes reported ($0.43) EPS vs. the consensus loss of ($0.57) and revenue of $392.9M vs. $363.3M expected; revenue was up ~28% year‑over‑year, supporting the stock move higher. Alkermes Q1 Earnings Release
• Positive Sentiment: Management highlighted LUMRYZ momentum on the earnings call as a key driver of commercial growth and reiterated product-level traction that underpins near‑term revenue strength. Alkermes Earnings Call: LUMRYZ Momentum Drives Growth
• Neutral Sentiment: The full earnings‑call transcript is available for investors who want line‑by‑line detail on guidance, cost drivers and commercial commentary. Useful for modeling assumptions and Q&A takeaways. Alkermes Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst/metric notes: Zacks and others highlight the beats on revenue and EPS and provide comparisons vs. estimates and year‑ago metrics — helpful context but largely reiterates reported results. ALKS Q1: Key Metrics vs Estimates (Zacks)
• Neutral Sentiment: Insider activity: an EVP sold ~2,034 shares under a pre‑arranged 10b5‑1 plan; small percentage impact and not an unusual liquidity event but worth noting. Insider Sale: David Joseph Gaffin
• Negative Sentiment: FY‑2026 guidance disappointed vs. consensus — Alkermes narrowed EPS guidance to roughly ($0.521)–($0.405), materially below the street’s ~($0.09) estimate; revenue guidance was trimmed to ~$1.7–1.8B (vs. consensus near $1.8B). This guidance gap is the main downside risk to the rally and may pressure forward estimates. Alkermes Reports First Quarter 2026 Financial Results

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.